Joel Greenblatt’s Summit Therapeutics Inc (SMMT) position
Reported position history, portfolio importance and verified filing changes from public SEC disclosures.
At a glance
The full verified relationship, including prior ownership episodes and exits where supported.
Gotham Asset Management first reported Summit Therapeutics Inc in Q2 2024. The reported position was reduced across later filings. Gotham Asset Management currently reports 15.73K shares. The latest verified filing showed: No change.
Position over time
See the same verified relationship through reported shares, portfolio weight or reported value.
Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.
What changed
Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.
Filing context
Quarter-end price $14.57 · Estimated holding basis $7.80
Filing context
Quarter-end price $18.96 · Estimated holding basis $7.80
Filing context
Quarter-end price $17.49 · Estimated holding basis $7.80
Filing context
Quarter-end price $20.66 · Estimated holding basis $7.80
Filing context
Quarter-end price $21.28 · Estimated holding basis $7.80
Filing context
Quarter-end price $19.29 · Estimated holding basis $7.80
Filing context
Quarter-end price $17.84 · Estimated holding basis $7.80
Filing context
Quarter-end price $21.90 · Estimated holding basis $7.80
Filing context
Quarter-end price $7.80 · Estimated holding basis $7.80
3 unchanged quarters are collapsed by default.
How important is Summit Therapeutics Inc in Gotham Asset Management’s reported portfolio?
Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.
SEC filing evidence
Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.
Derived from validated reported value and shares where supported.
Calculated from supported filing history.
This tracker follows Gotham Asset Management, LLC’s Form 13F disclosures—not Joel Greenblatt’s personal brokerage account. The filing is firm-level rather than a personal stock list. Form 13F reports quarter-end U.S.-listed positions and certain options, but it does not reveal exact trade dates, execution prices, short positions or the purpose of an option position.